Mizuho reiterated their hold rating on shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in a research note issued to investors on Wednesday. The brokerage currently has a $12.00 price target on the biopharmaceutical company’s stock.

Several other research analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a strong sell rating to a hold rating in a report on Tuesday, July 4th. UBS AG lowered their price target on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a report on Thursday, October 12th. TheStreet cut shares of Sucampo Pharmaceuticals from a c+ rating to a d rating in a report on Wednesday, August 2nd. Maxim Group set a $23.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, August 2nd. Finally, Leerink Swann initiated coverage on shares of Sucampo Pharmaceuticals in a report on Monday, August 21st. They set an outperform rating and a $15.00 price target for the company. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $16.50.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The company had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. During the same quarter in the previous year, the business posted $0.30 EPS. The firm’s revenue was up 5.9% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Given “Hold” Rating at Mizuho” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/sucampo-pharmaceuticals-inc-scmp-given-hold-rating-at-mizuho/1674059.html.

In related news, insider Jones W. Bryan bought 4,700 shares of the stock in a transaction dated Friday, August 4th. The stock was acquired at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the acquisition, the insider now owns 4,700 shares in the company, valued at approximately $49,820. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jason Patrick Meyenburg bought 4,000 shares of the stock in a transaction dated Wednesday, September 6th. The stock was bought at an average price of $12.13 per share, with a total value of $48,520.00. Following the acquisition, the insider now owns 30,228 shares in the company, valued at approximately $366,665.64. The disclosure for this purchase can be found here. Corporate insiders own 4.13% of the company’s stock.

Several institutional investors have recently modified their holdings of SCMP. Louisiana State Employees Retirement System boosted its holdings in shares of Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares in the last quarter. First Citizens Bank & Trust Co. acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at $116,000. JPMorgan Chase & Co. acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at $117,000. Karp Capital Management Corp acquired a new position in shares of Sucampo Pharmaceuticals in the 1st quarter valued at $119,000. Finally, Pinnacle Associates Ltd. acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at $122,000. Institutional investors and hedge funds own 55.54% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.